FDA GRANTS ORPHAN DRUG DESIGNATION FOR DROXIDOPA.

Biotech Business, March, 2007

Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP), Charlotte, N.C., has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to its drug candidate Droxidopa for the treatment of symptomatic neurogenic orthostatic hypotension (NOH) in patients with Primary Autonomic Failure, a group of diseases that includes Parkinson's Disease, Pure Autonomic Failure (PAF) and Multiple Systems Atrophy (MSA).

The Orphan Drug Act provides for economic incentives to encourage the development of drugs for diseases affecting fewer than 200,000 people in ...